Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crossover pharmacokinetics comparison of subcutaneous ianalumab injection devices in autoimmune disease
2023-508996-35-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised trial of ianalumab in systemic lupus erythematosus (SLE), Sjögren's syndrome and rheumatoid arthritis (RA) (2 arms), sponsored by Novartis. Planned start Sep 2024; status: authorised.
02
Drugs
ianalumab
03
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndromerheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2023-508996-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508996-35-00.